Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cells Consolidation in Newly Diagnosed Ph+ B-ALL
NCT06481228Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of LV20.19 CAR-T in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Disease-free Survival at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06481228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481228.